A reported ACL trial found no significant early benefit from an added nerve block, putting pain control and clinician-guided recovery after 35 in perspective.
On September 14, 2026, Orthogate published a sports-medicine evidence digest covering pain control and surgical decisions after anterior cruciate ligament (ACL) reconstruction. Its most relevant finding for early recovery came from a randomized trial of 100 adults undergoing primary ACL reconstruction.
The trial examined whether adding an adductor canal nerve block improved outcomes when patients already received local infiltration analgesia and multimodal pain treatment. For endurance athletes looking toward a return to training, the finding helps put an additional pain-control procedure in perspective. It also raises a more useful question: how does the complete recovery plan support the return of movement and function?
According to the Orthogate digest, adding an adductor canal block produced no significant improvement in the trial's reported early recovery measures. Those measures included opioid consumption and pain scores. They also included early quadriceps motor recovery and patient-reported outcomes at one week.
During the first 24 hours, mean opioid consumption was 28.5 oral morphine milligram equivalents with local infiltration analgesia alone. It was 31.2 with local infiltration plus the added block. The difference was not statistically significant, with p = 0.42. These figures describe medication consumption in the trial rather than recommended doses.
Pain scores in the post-anesthesia care unit and at 24 hours were described as clinically and statistically equivalent between groups. The researchers also assessed whether patients could perform an active straight-leg raise three hours after surgery. That early motor outcome did not differ significantly between groups, with p = 0.58.
At one week, the digest reported no significant differences in Quality of Recovery-15 scores or Knee Injury and Osteoarthritis Outcome Score domains. The added procedure therefore did not demonstrate an incremental benefit across the early outcomes reported in this particular care pathway.
In plain English, the extra block did not measurably improve the average early recovery experience when layered onto the pain treatment already provided. That is a finding about an addition to an established plan. It is not a finding that pain relief itself lacks value.
The study was a double-blind randomized controlled trial. The 100 adults were assigned equally to two groups. One received surgeon-administered local infiltration analgesia plus a sham saline injection. The other received local infiltration analgesia plus an ultrasound-guided adductor canal block.
Both groups also received standardized multimodal oral analgesics, according to Orthogate. This makes the comparison important: it was not a nerve block versus untreated postoperative pain. It tested whether the block added value beyond an existing combination of pain treatments.
The digest's clinical commentary questioned routinely adding the block in standard outpatient primary ACL reconstruction. It favored attention to the complete pain pathway rather than automatically layering on another procedure. That commentary is an interpretation of the reported trial, not an independently verified consensus statement.
A separate 2026 systematic review of return-to-sport testing included 43 studies and 17,350 participants with ACL reconstruction. Its summary identifies an association between hop-test performance and return-to-sport outcomes. That provides a broader functional context for interpreting early postoperative measurements.
The pain-control trial concerned primary ACL reconstruction. Its findings should not automatically be transferred to revision surgery or complex multiligament injuries. The digest provided no dedicated results for endurance athletes aged 35 to 65 and did not report detailed objective quadriceps-strength testing or longer-term strength recovery.
The trial also did not compare rehabilitation programs or establish a return-to-running timeline. A non-significant difference does not prove that the treatments are identical for every patient. Although the digest reported no adverse nerve-block events or related complications, that does not establish that regional anesthesia carries no risk.
The return-to-sport review's available summary does not establish hop testing alone as sufficient for clearance. Together, these boundaries keep the evidence in its proper place: early recovery findings can inform a clinical discussion without becoming an individualized anesthetic decision or sporting clearance.
Reendure's focus is evidence-based training and recovery guidance for ambitious athletes over 35. Here, that means keeping serious sporting goals while distinguishing pain management from the wider work of rebuilding function. The useful change is in how the recovery plan is evaluated, not in selecting or rejecting an anesthetic procedure without the treating team.
The research frames adequate analgesia as an enabler of recovery. It can help patients tolerate sleep and transfers as well as prescribed exercises and early walking. Those are meaningful purposes even when one additional intervention does not improve the average trial result.
For an athlete discussing surgery with qualified clinicians, the complete pathway is more informative than the name of a single block. Orthogate's commentary considers local infiltration alongside non-opioid medication and cryotherapy. The personal balance of those options belongs with the surgical and anesthesia teams.
Useful questions for that conversation include:
These questions keep the conversation focused on purpose. The goal is not to collect more interventions or to tolerate unnecessary pain. It is to understand how the chosen care plan supports participation in rehabilitation.
The broader recovery framework in the research includes pain and swelling control alongside restoration of knee motion. It also includes quadriceps activation and progressive loading. Neuromuscular control and sport-specific readiness belong in the same discussion.
Those goals are related, but they are not interchangeable. A useful interpretation of the evidence is to keep each visible in the clinical plan rather than allowing a pain score to stand in for the whole recovery process. The surgical and rehabilitation teams determine which activities are appropriate at each stage.
For the endurance athlete, this separates the ambition of returning to competition from the next rehabilitation objective. The long-term target can remain demanding while the immediate work follows the prescribed plan. There is no contradiction between patience during recovery and a serious commitment to future performance.
That distinction is also a useful lens for thinking about recovery after 35. The editorial priority is to identify the capacity being rebuilt rather than to judge every session by how closely it resembles normal training.
The research describes return to running or racing as requiring broader evaluation of strength and movement quality. Swelling response and confidence also matter within that assessment. The intended sport adds another layer because the recovery decision concerns a specific activity rather than an abstract label of being recovered.
For athletes whose goals include cycling or triathlon, the clinical conversation should distinguish returning to participation from returning to high-intensity competition. The same distinction applies to trail running and other endurance activities. Completing an activity and preparing to compete are different targets for the rehabilitation plan.
The return-to-sport review gives functional testing a place in that conversation. The practical interpretation is to use test results as part of a broader assessment that the treating team connects to sporting demands. This keeps an individual result meaningful without turning it into a universal pass mark.
A productive discussion therefore starts with what the athlete hopes to return to. The rehabilitation team can then explain how its assessments relate to that goal. This makes progress easier to understand without relying exclusively on elapsed time or subjective comfort.
For ambitious athletes aged 35 to 65, the lesson is not to lower expectations. It is to separate the long-term performance goal from the evidence needed for the next stage. A return plan becomes more coherent when each progression has a clear clinical purpose.
That approach fits the wider question of using recovery information in training-load decisions. In postoperative care, however, the relevant progression decisions belong with qualified clinicians who understand the operation and the athlete's circumstances.
The clearest practical shift is to ask what has improved and how it was assessed. Pain relief is one answer. Restored movement and developing strength are others. A sporting comeback should bring those strands together rather than allowing any one of them to dominate the plan.
For the veteran endurance athlete, this trial supports a clinician-guided return of movement and function rather than assuming that an extra pain-control procedure will produce a faster comeback.
Follow ReEndure for practical insights on endurance training, recovery, nutrition and healthy aging. Stay connected for new articles, research led guidance and ideas to help you perform better for longer.
Read practical ideas on endurance training, recovery, nutrition and healthy aging to keep progressing for years to come.
Read the Blog